VYNE Therapeutics Inc. is a biopharmaceutical company that specializes in the development and commercialization of innovative treatments for dermatological conditions. Its flagship product, AMZEEQ, is a topical minocycline designed for the treatment of inflammatory lesions associated with moderate-to-severe acne vulgaris in patients aged nine and older. VYNE is advancing several other products, including FMX103, which is in Phase III clinical trials for moderate-to-severe papulopustular rosacea, and FCD105, a topical combination foam currently in Phase II trials for acne vulgaris. Additionally, the company is developing Serlopitant, an oral NK1 receptor antagonist aimed at alleviating pruritus linked to conditions such as prurigo nodularis. Founded in 2003 and headquartered in Bridgewater, New Jersey, VYNE Therapeutics was previously known as Menlo Therapeutics Inc. before its name change in September 2020.
Gossamer Bio is a clinical-stage biopharmaceutical company based in San Diego that focuses on the discovery and development of innovative therapeutic products for unmet medical needs. Founded by former executives from Receptos, the company aims to leverage a strong in-licensing strategy and a team with extensive experience in immunology, inflammation, fibrosis, and oncology. Gossamer Bio's pipeline includes several promising candidates: Seralutinib, which targets pulmonary arterial hypertension; GB004, aimed at treating inflammatory bowel diseases such as ulcerative colitis and Crohn's disease; GB1275, designed for various oncology indications; and GB001, intended for moderate-to-severe eosinophilic asthma. Through these efforts, Gossamer Bio seeks to improve patient outcomes in critical therapeutic areas.
Peak Bio is a clinical-stage biopharmaceutical company dedicated to developing therapeutics for oncology, inflammatory diseases, and rare conditions. The company aims to address significant unmet medical needs through its innovative drug development efforts. By focusing on these critical areas, Peak Bio seeks to advance treatment options and improve patient outcomes.
Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York that specializes in developing novel psychotropic drugs aimed at treating mental illnesses. Established in 2019, the company focuses on creating innovative compounds that enhance the therapeutic benefits of classic psychedelics while improving safety, tolerability, duration, and efficacy. Gilgamesh addresses the growing global mental health crisis by providing treatments for various neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. Through a combination of medicinal chemistry and drug development expertise, the company aims to accelerate the availability of effective therapies, ultimately improving the quality of life for individuals suffering from central nervous system disorders.
NewLeaf Symbiotics is an agriculture technology company based in Saint Louis, Missouri, that specializes in the research, development, and commercialization of beneficial symbiotic bacteria aimed at enhancing plant health and increasing crop yields. The company focuses on natural bacteria, particularly pink pigmented facultative methylotrophs, which are utilized in various agricultural products for row crops, vegetables, fruits, and flowers. Through laboratory, greenhouse, and field trials, NewLeaf Symbiotics aims to provide sustainable agricultural solutions that assist farmers in combating plant diseases and improving overall agricultural productivity. Founded in 2011 and originally known as TrophoMax, LLC, the company rebranded to its current name in 2012.
NeXeption, LLC is a biopharmaceutical management company that brings together product opportunities, management expertise and the necessary funding to reach compelling partnership milestones. The NeXeption management team has a proven track record in raising capital, operating development stage companies and forming strategic partnerships to advance products for the benefit of patients.
Alimera Sciences is a pharmaceutical company focused on the research, development, and commercialization of prescription ophthalmic pharmaceuticals, particularly for diseases affecting the retina. The company’s primary product, ILUVIEN, is an intravitreal implant designed to treat diabetic macular edema (DME), a condition that poses a significant risk of vision loss in diabetic patients. ILUVIEN provides sustained release of the corticosteroid fluocinolone acetonide through a non-surgical procedure, allowing for a self-sealing wound. In addition to DME, the company also targets non-infectious uveitis affecting the posterior segment of the eye. Alimera operates in various international markets, including the United States, Germany, the United Kingdom, China, and the Middle East, utilizing both direct sales and distribution channels to reach physician offices, pharmacies, and hospitals. Founded in 2003 and headquartered in Alpharetta, Georgia, Alimera Sciences is dedicated to improving retinal health and vision preservation through innovative treatments.
Ceptaris Therapeutics, Inc. is a privately held specialty pharmaceutical company focused on developing a proprietary gel formulation of mechlorethamine hydrochloride for treating early-stage (stages I-IIA) mycosis fungoides, a form of Cutaneous T-Cell Lymphoma (CTCL). If approved, this investigational drug would be the first topical mechlorethamine product available for managing the signs and symptoms of this rare cancer. In addition to this primary focus, Ceptaris is also involved in developing other therapeutic products, including YT-1006, an NMDA antagonist aimed at treating neuropathic pain while minimizing side effects associated with NMDA. The company's innovative approaches enable healthcare professionals to address both dermatological and central nervous system disorders effectively.
Ceptaris Therapeutics, Inc. is a privately held specialty pharmaceutical company focused on developing a proprietary gel formulation of mechlorethamine hydrochloride for treating early-stage (stages I-IIA) mycosis fungoides, a form of Cutaneous T-Cell Lymphoma (CTCL). If approved, this investigational drug would be the first topical mechlorethamine product available for managing the signs and symptoms of this rare cancer. In addition to this primary focus, Ceptaris is also involved in developing other therapeutic products, including YT-1006, an NMDA antagonist aimed at treating neuropathic pain while minimizing side effects associated with NMDA. The company's innovative approaches enable healthcare professionals to address both dermatological and central nervous system disorders effectively.
Revance Therapeutics is a biotechnology company that focuses on developing, manufacturing, and commercializing neuromodulators for aesthetic and therapeutic applications. Its primary product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various clinical trials for treating conditions such as glabellar lines, cervical dystonia, adult upper limb spasticity, and plantar fasciitis, while also being explored for chronic migraine treatment. Additionally, Revance is developing topical formulations of DAXI and a biosimilar to BOTOX. The company has established collaborations for the development and commercialization of these products. Revance also offers a portfolio of aesthetic products, including the RHA Collection of dermal fillers and the HintMD platform. Founded in 1999 and headquartered in Newark, California, Revance Therapeutics was previously known as Essentia Biosystems.
Private Equity Round in 2011
Fisker, Inc. is an electric vehicle design and manufacturing company based in Manhattan Beach, California. Committed to sustainability, Fisker aims to provide eco-friendly mobility solutions that evoke emotional connections with users. The company seeks to revolutionize the automotive industry by focusing on the development of desirable electric vehicles. Fisker’s vision is rooted in the ambition to create a cleaner future through innovative e-mobility services. Historically, Fisker Automotive gained recognition for the Fisker Karma, one of the first luxury plug-in hybrid electric vehicles, which debuted in 2008. Although production of the Karma was halted in 2012 due to supplier bankruptcy issues, Fisker continues to advance its mission in the electric vehicle market.
Revance Therapeutics is a biotechnology company that focuses on developing, manufacturing, and commercializing neuromodulators for aesthetic and therapeutic applications. Its primary product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various clinical trials for treating conditions such as glabellar lines, cervical dystonia, adult upper limb spasticity, and plantar fasciitis, while also being explored for chronic migraine treatment. Additionally, Revance is developing topical formulations of DAXI and a biosimilar to BOTOX. The company has established collaborations for the development and commercialization of these products. Revance also offers a portfolio of aesthetic products, including the RHA Collection of dermal fillers and the HintMD platform. Founded in 1999 and headquartered in Newark, California, Revance Therapeutics was previously known as Essentia Biosystems.
Fisker, Inc. is an electric vehicle design and manufacturing company based in Manhattan Beach, California. Committed to sustainability, Fisker aims to provide eco-friendly mobility solutions that evoke emotional connections with users. The company seeks to revolutionize the automotive industry by focusing on the development of desirable electric vehicles. Fisker’s vision is rooted in the ambition to create a cleaner future through innovative e-mobility services. Historically, Fisker Automotive gained recognition for the Fisker Karma, one of the first luxury plug-in hybrid electric vehicles, which debuted in 2008. Although production of the Karma was halted in 2012 due to supplier bankruptcy issues, Fisker continues to advance its mission in the electric vehicle market.
Fisker, Inc. is an electric vehicle design and manufacturing company based in Manhattan Beach, California. Committed to sustainability, Fisker aims to provide eco-friendly mobility solutions that evoke emotional connections with users. The company seeks to revolutionize the automotive industry by focusing on the development of desirable electric vehicles. Fisker’s vision is rooted in the ambition to create a cleaner future through innovative e-mobility services. Historically, Fisker Automotive gained recognition for the Fisker Karma, one of the first luxury plug-in hybrid electric vehicles, which debuted in 2008. Although production of the Karma was halted in 2012 due to supplier bankruptcy issues, Fisker continues to advance its mission in the electric vehicle market.
Revance Therapeutics is a biotechnology company that focuses on developing, manufacturing, and commercializing neuromodulators for aesthetic and therapeutic applications. Its primary product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various clinical trials for treating conditions such as glabellar lines, cervical dystonia, adult upper limb spasticity, and plantar fasciitis, while also being explored for chronic migraine treatment. Additionally, Revance is developing topical formulations of DAXI and a biosimilar to BOTOX. The company has established collaborations for the development and commercialization of these products. Revance also offers a portfolio of aesthetic products, including the RHA Collection of dermal fillers and the HintMD platform. Founded in 1999 and headquartered in Newark, California, Revance Therapeutics was previously known as Essentia Biosystems.
Fisker, Inc. is an electric vehicle design and manufacturing company based in Manhattan Beach, California. Committed to sustainability, Fisker aims to provide eco-friendly mobility solutions that evoke emotional connections with users. The company seeks to revolutionize the automotive industry by focusing on the development of desirable electric vehicles. Fisker’s vision is rooted in the ambition to create a cleaner future through innovative e-mobility services. Historically, Fisker Automotive gained recognition for the Fisker Karma, one of the first luxury plug-in hybrid electric vehicles, which debuted in 2008. Although production of the Karma was halted in 2012 due to supplier bankruptcy issues, Fisker continues to advance its mission in the electric vehicle market.
Ceptaris Therapeutics, Inc. is a privately held specialty pharmaceutical company focused on developing a proprietary gel formulation of mechlorethamine hydrochloride for treating early-stage (stages I-IIA) mycosis fungoides, a form of Cutaneous T-Cell Lymphoma (CTCL). If approved, this investigational drug would be the first topical mechlorethamine product available for managing the signs and symptoms of this rare cancer. In addition to this primary focus, Ceptaris is also involved in developing other therapeutic products, including YT-1006, an NMDA antagonist aimed at treating neuropathic pain while minimizing side effects associated with NMDA. The company's innovative approaches enable healthcare professionals to address both dermatological and central nervous system disorders effectively.
Paracor Medical is an innovative medical device company focused on providing unique, technology-driven solutions for the treatment of heart failure. Founded in 1999, Paracor was established to pursue new and innovative ways to treat heart failure (HF) that would not require the patient to undergo open chest surgery. Paracor engineers recognized that a mechanical approach to reducing the workload of a failing, diseased heart muscle could be a new and effective solution.
Amicus Therapeutics is a biotechnology company dedicated to discovering, developing, and commercializing therapies for rare and orphan diseases. The company is known for its product Galafold, an orally administered small molecule pharmacological chaperone specifically designed for treating Fabry disease. Amicus is also advancing its clinical pipeline, including a Phase 3 study of AT-GAA for Pompe disease. The company focuses on creating novel therapies, particularly pharmacological chaperones, which are intended to stabilize and enhance the activity of misfolded enzymes in patients. This approach may improve treatment outcomes, especially when used in conjunction with enzyme replacement therapy. Amicus Therapeutics was founded in 2002 and is headquartered in Cranbury, New Jersey, collaborating with institutions like Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.
SkyPilot Networks is a prominent provider of broadband wireless equipment designed for service providers, municipalities, and public safety agencies to efficiently deploy various network services. These services include last-mile Internet access, voice over IP, Wi-Fi hotspots, and video surveillance. The company's innovative solution employs a patented multi-hop point-to-multipoint architecture that enhances reach, reduces interference, and optimizes spectral efficiency. This technology results in a scalable, reliable, and deterministic broadband wireless network that simplifies design, increases deployment flexibility, and lowers both equipment and operational costs. SkyPilot's products include the SkyPilot Connector Mini and Pro, which offer cost-effective customer premises equipment for long-range connectivity, and the SkyPilot EMS, an element management system that aids in the deployment and management of wireless mesh networks. With a proven track record, SkyPilot has delivered its systems to customers in over 50 countries and is headquartered in Santa Clara, California.
Mercator MedSystems, Inc. is a medical technology company based in Emeryville, California, specializing in catheter-guided microfluid injection systems for the targeted delivery of therapeutic agents. The company offers Cricket and Bullfrog micro-infusion catheters, which facilitate the direct injection of therapies through blood vessel walls into deep tissues. These products address conditions such as blood vessel restenosis, inflammation following vascular injury, and peripheral artery disease. Mercator's technology allows for the infusion of drugs, genes, and cells without compromising their viability or potency, making it suitable for therapies ranging from plaque stabilization in diseased vessels to stem cell transplantation and gene therapies. By enabling site-specific delivery, Mercator MedSystems aims to enhance patient outcomes in vascular disease, oncology, and regenerative medicine, while paving the way for innovative treatments in these areas. The company was established in 1999 and was previously known as Endobionics, Inc.
FlowMedica is a medical device company that specializes in intravascular systems for Targeted Renal Therapy, addressing renal conditions linked to cardiovascular disease, cancer, and surgical procedures. The company's flagship products include the Benephit CV Infusion System, which allows physicians to deliver therapeutic agents directly into the renal arteries via an infusion catheter, while facilitating simultaneous coronary procedures through a single access site in the femoral artery. Additionally, FlowMedica offers the Benephit XTMini Infusion System, designed for bilateral infusion to the kidneys, particularly beneficial for patients with smaller vascular anatomies. By providing a targeted approach to renal therapy, FlowMedica's devices serve as an effective alternative to traditional systemic intravenous infusion methods, enabling precise delivery in various clinical scenarios.
Amicus Therapeutics is a biotechnology company dedicated to discovering, developing, and commercializing therapies for rare and orphan diseases. The company is known for its product Galafold, an orally administered small molecule pharmacological chaperone specifically designed for treating Fabry disease. Amicus is also advancing its clinical pipeline, including a Phase 3 study of AT-GAA for Pompe disease. The company focuses on creating novel therapies, particularly pharmacological chaperones, which are intended to stabilize and enhance the activity of misfolded enzymes in patients. This approach may improve treatment outcomes, especially when used in conjunction with enzyme replacement therapy. Amicus Therapeutics was founded in 2002 and is headquartered in Cranbury, New Jersey, collaborating with institutions like Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.
Deem, Inc. is a technology company specializing in Commerce-as-a-Service (CaaS) that streamlines business travel and expense management for organizations. Founded in 1999 and headquartered in San Francisco, Deem provides an integrated cloud suite of applications that allow companies to manage travel, expenses, and purchases effectively. Its platform enables employees to book flights, hotels, and ground transportation easily, enhancing productivity and efficiency. Deem also offers merchants opportunities to sell their products and services intelligently through promotions and discounts, while allowing companies to syndicate additional offerings to existing customers. This approach helps businesses save costs on transactions and maintain compliance with spending policies. Deem operates as a subsidiary of Enterprise Holdings, Inc. since 2019, continuing its mission to simplify and optimize the business travel experience for both travelers and organizations.
SkyPilot Networks is a prominent provider of broadband wireless equipment designed for service providers, municipalities, and public safety agencies to efficiently deploy various network services. These services include last-mile Internet access, voice over IP, Wi-Fi hotspots, and video surveillance. The company's innovative solution employs a patented multi-hop point-to-multipoint architecture that enhances reach, reduces interference, and optimizes spectral efficiency. This technology results in a scalable, reliable, and deterministic broadband wireless network that simplifies design, increases deployment flexibility, and lowers both equipment and operational costs. SkyPilot's products include the SkyPilot Connector Mini and Pro, which offer cost-effective customer premises equipment for long-range connectivity, and the SkyPilot EMS, an element management system that aids in the deployment and management of wireless mesh networks. With a proven track record, SkyPilot has delivered its systems to customers in over 50 countries and is headquartered in Santa Clara, California.
Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.
LuMend Inc. designs, develops, manufactures and markets medical devices intended to enable physicians to safely, predictably and cost effectively cross Chronic Total Occlusions (CTO) in the coronary vasculature, allowing subsequent conventional guide wire placement across target stenotic lesions. The company was founded in 1996 by two pioneering interventional cardiologists, John Simpson, PhD, MD, and Matthew Selmon, MD.
Labcyte Inc. is a laboratory instrumentation company based in San Jose, California, specializing in acoustic droplet ejection (ADE) technology for life sciences applications. Established in 2000, Labcyte develops innovative solutions for drug discovery, genomic research, cancer research, and personalized medicine through its precise liquid dispensing technology. This technology utilizes focused acoustic energy to eject nanoliter-scale droplets of fluid, allowing for high accuracy and reduced consumption of materials. Labcyte's product offerings include automation systems, laboratory workstations, and control software aimed at enhancing research efficiency and data reliability. The company operates as a subsidiary of Beckman Coulter, Inc. and maintains additional offices across multiple countries, including Canada, the United Kingdom, and Japan.
SkyPilot Networks is a prominent provider of broadband wireless equipment designed for service providers, municipalities, and public safety agencies to efficiently deploy various network services. These services include last-mile Internet access, voice over IP, Wi-Fi hotspots, and video surveillance. The company's innovative solution employs a patented multi-hop point-to-multipoint architecture that enhances reach, reduces interference, and optimizes spectral efficiency. This technology results in a scalable, reliable, and deterministic broadband wireless network that simplifies design, increases deployment flexibility, and lowers both equipment and operational costs. SkyPilot's products include the SkyPilot Connector Mini and Pro, which offer cost-effective customer premises equipment for long-range connectivity, and the SkyPilot EMS, an element management system that aids in the deployment and management of wireless mesh networks. With a proven track record, SkyPilot has delivered its systems to customers in over 50 countries and is headquartered in Santa Clara, California.
Speedera Networks, Inc. was founded in 1999 and is headquartered in Santa Clara, California. The company specializes in distributed application hosting and content delivery services, catering to both industry and government sectors. It offers a range of on-demand services designed to address challenges related to performance, scalability, availability, and security of distributed applications and websites. In 2005, Speedera Networks was acquired by Akamai Technologies Inc.
Labcyte Inc. is a laboratory instrumentation company based in San Jose, California, specializing in acoustic droplet ejection (ADE) technology for life sciences applications. Established in 2000, Labcyte develops innovative solutions for drug discovery, genomic research, cancer research, and personalized medicine through its precise liquid dispensing technology. This technology utilizes focused acoustic energy to eject nanoliter-scale droplets of fluid, allowing for high accuracy and reduced consumption of materials. Labcyte's product offerings include automation systems, laboratory workstations, and control software aimed at enhancing research efficiency and data reliability. The company operates as a subsidiary of Beckman Coulter, Inc. and maintains additional offices across multiple countries, including Canada, the United Kingdom, and Japan.
Conductus specializes in producing superconducting wire, known as Conductus®, which is utilized in the creation of superconductor electrical devices across various applications. This high current carrying conductor offers substantial performance improvements, enhanced power density, reduced size, and significant cost advantages compared to traditional copper and aluminum wire. The wire is manufactured using a proprietary deposition process called RCE-CDR. Additionally, Conductus develops electronic components and systems based on high-temperature superconductors for the global telecommunications market, utilizing thin-film technology derived from yttrium barium copper oxide. Their products cater to various telecommunications standards, including TDMA, CDMA, GSM, and analog base stations.